Temporal Comparison
Track findings across up to three prior mammograms
Software · Cloud SaaSCompany source
Company profile
About ScreenPoint Medical BV
ScreenPoint Medical BV is a medical imaging AI company specializing in breast cancer detection technology. The company develops Transpara Breast AI, a comprehensive suite of AI-powered applications designed for every step of the breast imaging continuum. Born from collaboration between two leading researchers in image processing, ScreenPoint Medical maintains strong roots in applied academia while delivering clinically validated solutions to healthcare providers worldwide. Transpara Breast AI serves as a 'second pair of eyes' for radiologists, offering enhanced detection capabilities across both 2D (FFDM) and 3D (DBT) mammography. The platform is vendor-agnostic and integrates seamlessly with existing PACS systems, AI platforms, and imaging technologies. The solution addresses critical challenges facing breast imaging programs including radiologist shortages, staff burnout, rising volumes, and increasing patient expectations. The company's product suite includes Transpara Detection for cancer identification, Transpara Density for breast density assessment, and Temporal Comparison for tracking findings across multiple prior mammograms. ScreenPoint Medical's technology is backed by the most extensive clinical evidence portfolio in breast imaging AI, including 55+ peer-reviewed publications analyzing over 11 million mammograms. The company is the only breast AI provider selected for multiple randomized controlled trials, including the landmark MASAI study in Sweden, PRISM trial in the USA, and AIMS trial in Norway. Transpara is deployed across 30+ countries, serving leading healthcare institutions, screening programs, and radiology practices globally.
Company description ScreenPoint Medical BV official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at ScreenPoint Medical BV?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer
- Mammography screening
Who it serves
- Academic Medical Centers
- Health Systems
- Radiology Practices
- Screening Programs
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: Aidoc AI platform, Ferrum Health Model Hub, Fujifilm imaging systems, Ikonopedia, Microsoft Precision Imaging Network, PACS systems.
Geographic context
Markets30+ countries globally · Germany · Netherlands · Norway · Portugal · Spain · Sweden · USA
Company sourceOfficial website
Company milestones
Platform expansion
Selected for $16M PRISM RCT in USA (September 2025), MASAI RCT results published in The Lancet (January 2026), AITIC study published in Nature Medicine (March 2026)
Partnerships
Recorded partners
- Aidoc
- Ferrum Health
- Fujifilm Healthcare Americas
- Ikonopedia
- Microsoft (Precision Imaging Network)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Transpara Density
Automated breast density assessment with BI-RADS-like classification
Software · Cloud SaaSCompany source
Transpara Detection
AI-powered breast cancer detection for 2D and 3D mammography
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial.Nature medicine · Apr 1, 2026
Breast cancer in women after withdrawing from an increased-risk MRI screening program.European radiology · Dec 1, 2025
The use of artificial intelligence (AI) to safely reduce the workload of breast cancer screening: a retrospective simulation study.Acta radiologica (Stockholm, Sweden : 1987) · Nov 1, 2025
AI Should Read Mammograms Only When Confident: A Hybrid Breast Cancer Screening Reading Strategy.Radiology · Aug 1, 2025
AI as an independent second reader in detection of clinically relevant breast cancers within a population-based screening programme in the Netherlands: a retrospective cohort study.The Lancet. Digital health · Aug 1, 2025
An Exploration of Discrepant Recalls Between AI and Human Readers of Malignant Lesions in Digital Mammography Screening.Diagnostics (Basel, Switzerland) · Jun 19, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Transpara (2.1.0)K241831 · 510k · Nov 25, 2024
Transpara Density 1.0.0K232096 · 510k · Dec 11, 2023
Transpara 1.7.2K221347 · 510k · Aug 3, 2022
Transpara 1.7.0K210404 · 510k · Jun 2, 2021
TransparaK193229 · 510k · Mar 5, 2020
TransparaK192287 · 510k · Dec 10, 2019
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
29% increase in cancer detection
MASAI RCT vs double-reading standard of care
44% reduction in screen-reading workload
MASAI RCT in double-reading environment
12% reduction in interval cancer rate
MASAI RCT
99.97% negative predictive value
Unmarked studies (70% of screening population)
26% time savings on DBT studies
Van Winkel et al, 2021
60%+ workload reduction
AITIC study for low-risk cases
AITIC Spain Prospective Trial
Autonomous AI for low-risk case exclusion
Over 60% reduction in radiologist workload by safely excluding low-risk studies from human review
MASAI RCT Sweden
Population-based breast cancer screening with AI assistance
29% increase in cancer detection, 44% decrease in workload, 12% reduction in interval cancer rate
CUF Portugal
Breast cancer screening with high confidence in negative results
High negative predictive value for Low Risk results confirmed through internal audit
Hospital Universitario Reina Sofia
Prospective implementation in screening program
Significantly improved detection performance with higher sensitivity at high specificity
Linköping University / Ostergotland County
Real-life screening setting implementation to improve quality and reduce workload
Safely reduce workload of breast radiologists while improving screening quality
Referenzzentrum Mammographie Germany
Risk-adapted screening and resource optimization
Discriminating studies requiring more attention and enabling single reading for selected cases
University Diagnostic Medical Imaging
3D mammography workflow enhancement with risk-based prioritization
Increased mammography workflow and faster care for high-risk patients
University Radiology Group
Screening mammography workflow enhancement and risk-based triage
Increased mammography workflow efficiency with focus on higher risk cases
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Dr. João Abrantes
Diagnostic Radiologist
Dr. Roger Yang
President
Dr. Alvarez Benito
Consultant Radiologist
Håkan Gustafsson
Adjunct Associate Professor
Professor Sylvia H Heywang-Köbrunner
Radiologist, Head of Referenzzentrum Mammographie
Dr. Daniel Gurrell
VP and Associate Medical Director
06 · Company updates
Updates from ScreenPoint Medical BV
Recent articles published on ScreenPoint Medical BV's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.